Literature DB >> 22025017

Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context.

Paul Timpson1, Ewan J McGhee, Zahra Erami, Max Nobis, Jean A Quinn, Mike Edward, Kurt I Anderson.   

Abstract

Cell migration is fundamental to many aspects of biology, including development, wound healing, the cellular responses of the immune system, and metastasis of tumor cells. Migration has been studied on glass coverslips in order to make cellular dynamics amenable to investigation by light microscopy. However, it has become clear that many aspects of cell migration depend on features of the local environment including its elasticity, protein composition, and pore size, which are not faithfully represented by rigid two dimensional substrates such as glass and plastic. Furthermore, interaction with other cell types, including stromal fibroblasts and immune cells, has been shown to play a critical role in promoting the invasion of cancer cells. Investigation at the molecular level has increasingly shown that molecular dynamics, including response to drug treatment, of identical cells are significantly different when compared in vitro and in vivo. Ideally, it would be best to study cell migration in its naturally occurring context in living organisms, however this is not always possible. Intermediate tissue culture systems, such as cell derived matrix, matrigel, organotypic culture (described here) tissue explants, organoids, and xenografts, are therefore important experimental intermediates. These systems approximate certain aspects of an in vivo environment but are more amenable to experimental manipulation such as use of stably transfected cell lines, drug treatment regimes, long term and high-resolution imaging. Such intermediate systems are especially useful as proving grounds to validate probes and establish parameters required to image the dynamic response of cells and fluorescent reporters prior to undertaking imaging in vivo. As such, they can serve an important role in reducing the need for experiments on living animals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025017      PMCID: PMC3227204          DOI: 10.3791/3089

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


4 mm punch biopsies acquired from human forearm are placed in MEM supplemented 100 units / ml penicillin, 100 μg / ml streptomycin, and 0.25 μg / ml Fungizone. Trim any subcutaneous fat and finely chop the biopsy into small pieces by rocking a number 24 scalpel blade against the bottom of the petri dish. Place tissue slurry in a 25 cm2 tissue culture flask with primary fibroblast growth media (MEM supplemented with 10% FCS, 100 units / ml penicillin, 100 μg / ml streptomycin, and 25 μg / ml Fungizone) added until the surface of flask is covered but liquid depth is insufficient for tissue to float. Following 3 days incubation at 37°C in a humidified atmosphere of 5% CO2 , add 3 ml of primary fibroblast growth media. Following another 3 days incubation change media with fresh primary fibroblast growth media, or if cells are nearly confluent they may be split 1:4 into fresh media. (Fungizone can be omitted from this point onwards).

Protocol

2. Stage I - Preparation of collagen I from rat tails

Note: Protocol for approximately 12-14 adolescent (fresh or frozen) rat tails Prepare rat tail by washing in 70% ethanol and remove tendons as follows: Remove skin from rat tail by slicing in the middle of the tail from top to bottom with a scalpel and pealing along the length of the tail. Detach tendon from the core of the proximal region of the tail. Remove tendon toward the distal region of the tail avoiding the sheath using toothed forceps. Extract 1 g of tendon / 250 ml of 0.5 M acetic acid by stirring at 4°C for 48 h. Centrifuge the extract (7,500 x g) for 30 mins and discard the pellet. Add an equal volume of 10% (w/v) NaCl to the supernatant, and stir for 30-60 min. Centrifuge (10,000 x g) for 30 mins, discard the supernatant, and re-dissolve the precipitate in 0.25 M acetic acid at ˜ 1:1 ratio by stirring for 24 h at 4°C. Dialyze the collagen solution against 6-8 changes of 6L ˜17.5 mM acetic acid (1 ml glacial acetic acid per liter of cold water, change 2 x daily). Centrifuge dialysed collagen at 30,000 x g for 1.5 hrs. Remove supernatant and place in sterile flask. Adjust the collagen I concentration to ˜2 mg/ml using 0.5 mM acetic acid at 4°C. Assemble the mix using cold reagents at 4°C in a pre-chilled bottle. Keep collagen I on ice. For one T75 flask of confluent primary fibroblasts (˜ cell number 1 x 106) use: 25 ml rat tail collagen (approx conc 2mg/ml) 3 ml 10xMEM 0.22 M NaOH: first, add 2ml, then drop-wise whilst stirring, until the collagen turns orange, but not pink (usually up to 3 ml). Approximate pH = 7.2. Note: It is important to ensure that the medium/gel remains neutral or slightly acidic as fibroblasts will not contract the gel if exposed to even slightly alkaline conditions. Trypsinise the fibroblasts, spin at 400 x g for 5 mins and remove supernatant. During 5 mins spin above: Prepare 12 x 35 mm plastic dishes - normally achieve 12 dishes from one flask of fibroblasts/collagen mix. Re-suspend fibroblasts in 3 ml FCS and immediately add to the collagen mix and stir. Plate approximately 2.5 ml of collagen/fibroblast per dish as quickly as possible. Try to avoid bubbles and collagen setting. Let the collagen set at 37°C in a humidified atmosphere of 5% CO2 in air for 10 mins. Add 1ml of fibroblast growth media (DMEM+ 10% FCS). Detach the collagen/fibroblast matrix from the sides of the dish using a pipette. Next day: Add 1ml of fibroblast growth media (DMEM + 10% FCS). Change media every other day. Allow collagen/fibroblast matrix to contract for approximately 8 days, until they fit in a 24-well dish (Contraction from ˜3.5 cm to 1.5 cm in diameter, see Figure 1).

3. Stage II - Setting up the 3D matrix with embedded fibroblasts (allow to contract for 8 days).

Note: The collagen concentration should be adjusted to suit the application. The more dilute the collagen solution, the faster it will be contracted by the fibroblasts. Slight differences in contraction rate will be experienced with different batches of collagen at the same concentration. Similarly, different fibroblast cultures will contract the collagen gels at different rates, and the more fibroblasts present, the faster the rate of contraction. Collagen concentration and fibroblast density can therefore by adjusted to modify the rate of contraction, and the final density of the collagen gel.

4. Stage II - Plating cells of interest on top of the matrix

Note: Sterilize all forceps and equipment with ethanol before use. Using blunt forceps, gently move contracted matrix to 24-well dish. Make sure it does not fold. Prepare suspension of cells of interest at approximately 4 x 104 /ml and plate 1ml (after trypsinising, spin cells to get rid of trypsin) on top of the matrix. Actual number of cells needed will vary depending on cell type used. Cell medium should be normal growth medium for the cells of interest. Allow cells to grow to confluence on top of the matrix, approximately 3-5 days. Cut stainless steel grids to create a tripod and autoclave prior to use (See Figure 2). Place sterile grid in 6 cm dish, add growth media to a level above the grid (approx 10.5ml). Place matrix on the grid and gently aspirate media so the bottom of the matrix is in contact with media but not submerged. This is referred to as the air/liquid interface, which creates a gradient that promotes invasion. Replace medium every two days (See Figure 2). Live cell, contextual imaging using fluorescent cells can be imaged at this stage or earlier. The contracted or fibrillar collagen I can be imaged using second harmonic generation (SHG, See figure 3). Using multi-photon excitation combined with wide-field detection we find that SHG can be imaged at least 100 μm into the matrix, whereas cells expressing cytoplasmic GFP can be imaged at least 200 μm deep.

5. Stage III - Transferring the matrix to a grid for invasion (approximately 0-21 days)

Note: With respect to quantification of invasion, the day on which matricies are placed on the grids defines Day 0. Placement on grids generates a gradient of cell culture media that promotes invasion into the matrix. Samples can be imaged over the next 1 - 21 days (or longer) to assess biological processes such as invasion, proliferation, survival or differentiation (See reference list). Add 5 ml of 4% PFA in a Falcon tube. Transfer the matrix onto a flat surface. Cut the matrix in half with a fresh clean scalpel (as you will be staining the cross section), lift the matrix with scalpel and transfer to 4% PFA, fix over night. Organotypic matrices are now ready to stain with antibody/stain of choice (See Figure 3).

7. Representative results:

Figure 1Example of fibroblast-contracted collagen I. Mixture of fibroblast and rat tail collagen detached from the petri dish and allowed to contract over 6-8 days. Figure 2Organotypic assay progression. A, schematic of organotypic set up and progression. B, Example of collagen/fibroblast matrix on top of stainless steel, sterile grid to create air/liquid interface. Figure 3Applications of organotypic assay. A, B non-invasive and invasive pancreatic ductal adenocarcinoma (PDAC) cells invading over time with organotypic matrix. C, living skin equivalent showing a stratified epidermis on a fibroblast-contracted collagenous dermal component. D, C8161 melanoma cells invading in to a fibroblast-contracted collagenous dermal equivalent. E, invasive PDAC cells (green) interacting and invading with fibroblasts (red) within the organotypic matrix. F, invasive PDAC cells (green) interacting with a degrading surrounding extracellular matrix (purple) visualised using multiphoton -based second harmonic generation.

Discussion

Here we present a method for production of a 3-dimensional matrix suitable for studies of invasive cell migration 6-8. The matrix consists of collagen type 1 fibrils, which are contracted over a period of several days by primary human epidermal fibroblasts. The collagen is prepared by acid extraction, not enzymatic digestion, which preserves reactivity at the poly-peptide ends and promotes cross-linking of collagen fibrils into larger aggregates upon neutralization of buffer conditions 9. This results in a re-constituted gel which more closely mimics the features of collagen in vivo and has important consequences for the invasive properties of cells cultured in the gels. It does not matter whether fresh or frozen starting material is used, but use of adolescent rat tails is important because collagen cross-linking is more labile in younger animals. Collagen I from younger animals is therefore easier to extract, and re-constitutes with higher fidelity. The collagen matrix can be fixed and stained with antibodies directed against either invasive tumor cells or stromal fibroblasts 2,10 and are highly useful for testing the efficacy of drugs which might inhibit invasion 5,6. Although this protocol suggests the use of primary human skin fibroblasts, it is feasible to use primary fibroblasts from other tissue types, according to the type of tissue under investigation. It is also possible to establish cultures using immortalized fibroblasts, including cells which have been stably transfected with fluorescent protein conjugates. In this way both stromal and tumor cells can be labelled to visualise cell-cell interactions during invasion 11.

Disclosures

We have nothing to disclose.
  11 in total

1.  Development of a quantitative method to analyse tumour cell invasion in organotypic culture.

Authors:  M L Nyström; G J Thomas; M Stone; I C Mackenzie; I R Hart; J F Marshall
Journal:  J Pathol       Date:  2005-03       Impact factor: 7.996

2.  Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumour growth and invasion.

Authors:  M Edward; C Gillan; D Micha; R H Tammi
Journal:  Carcinogenesis       Date:  2005-03-03       Impact factor: 4.944

Review 3.  Modeling tissue morphogenesis and cancer in 3D.

Authors:  Kenneth M Yamada; Edna Cukierman
Journal:  Cell       Date:  2007-08-24       Impact factor: 41.582

4.  Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor.

Authors:  Antonia Patsialou; Jeffrey Wyckoff; Yarong Wang; Sumanta Goswami; E Richard Stanley; John S Condeelis
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

5.  Keratinocyte regulation of TGF-beta and connective tissue growth factor expression: a role in suppression of scar tissue formation.

Authors:  Syed Basith Amjad; Robert Carachi; Michael Edward
Journal:  Wound Repair Regen       Date:  2007 Sep-Oct       Impact factor: 3.617

6.  Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo.

Authors:  N E Fusenig; D Breitkreutz; R T Dzarlieva; P Boukamp; A Bohnert; W Tilgen
Journal:  J Invest Dermatol       Date:  1983-07       Impact factor: 8.551

7.  Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug development.

Authors:  Alan Serrels; Paul Timpson; Marta Canel; Juliane P Schwarz; Neil O Carragher; Margaret C Frame; Valerie G Brunton; Kurt I Anderson
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

8.  4-Methylumbelliferone inhibits tumour cell growth and the activation of stromal hyaluronan synthesis by melanoma cell-derived factors.

Authors:  M Edward; J A Quinn; S M Pasonen-Seppänen; B A McCann; R H Tammi
Journal:  Br J Dermatol       Date:  2010-02-15       Impact factor: 9.302

9.  Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.

Authors:  Paul Timpson; Ewan J McGhee; Jennifer P Morton; Alex von Kriegsheim; Juliane P Schwarz; Saadia A Karim; Brendan Doyle; Jean A Quinn; Neil O Carragher; Mike Edward; Michael F Olson; Margaret C Frame; Valerie G Brunton; Owen J Sansom; Kurt I Anderson
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

10.  Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited.

Authors:  Farideh Sabeh; Ryoko Shimizu-Hirota; Stephen J Weiss
Journal:  J Cell Biol       Date:  2009-03-30       Impact factor: 10.539

View more
  39 in total

Review 1.  Developments in preclinical cancer imaging: innovating the discovery of therapeutics.

Authors:  James R W Conway; Neil O Carragher; Paul Timpson
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

Review 2.  Screening out irrelevant cell-based models of disease.

Authors:  Peter Horvath; Nathalie Aulner; Marc Bickle; Anthony M Davies; Elaine Del Nery; Daniel Ebner; Maria C Montoya; Päivi Östling; Vilja Pietiäinen; Leo S Price; Spencer L Shorte; Gerardo Turcatti; Carina von Schantz; Neil O Carragher
Journal:  Nat Rev Drug Discov       Date:  2016-09-12       Impact factor: 84.694

3.  Annexin A6 and Late Endosomal Cholesterol Modulate Integrin Recycling and Cell Migration.

Authors:  Ana García-Melero; Meritxell Reverter; Monira Hoque; Elsa Meneses-Salas; Meryem Koese; James R W Conway; Camilla H Johnsen; Anna Alvarez-Guaita; Frederic Morales-Paytuvi; Yasmin A Elmaghrabi; Albert Pol; Francesc Tebar; Rachael Z Murray; Paul Timpson; Carlos Enrich; Thomas Grewal; Carles Rentero
Journal:  J Biol Chem       Date:  2015-11-17       Impact factor: 5.157

4.  The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

Authors:  I Roth; H Campbell; C Rubio; C Vennin; M Wilson; A Wiles; G Williams; A Woolley; P Timpson; M V Berridge; N Fleming; M Baird; A W Braithwaite
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

5.  Aqueous two-phase printing of cell-containing contractile collagen microgels.

Authors:  Christopher Moraes; Arlyne B Simon; Andrew J Putnam; Shuichi Takayama
Journal:  Biomaterials       Date:  2013-09-10       Impact factor: 12.479

6.  Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.

Authors:  Sunny Z Wu; Daniel L Roden; Chenfei Wang; Holly Holliday; Kate Harvey; Aurélie S Cazet; Kendelle J Murphy; Brooke Pereira; Ghamdan Al-Eryani; Nenad Bartonicek; Rui Hou; James R Torpy; Simon Junankar; Chia-Ling Chan; Chuan En Lam; Mun N Hui; Laurence Gluch; Jane Beith; Andrew Parker; Elizabeth Robbins; Davendra Segara; Cindy Mak; Caroline Cooper; Sanjay Warrier; Alistair Forrest; Joseph Powell; Sandra O'Toole; Thomas R Cox; Paul Timpson; Elgene Lim; X Shirley Liu; Alexander Swarbrick
Journal:  EMBO J       Date:  2020-08-13       Impact factor: 11.598

7.  Ral GTPases promote breast cancer metastasis by controlling biogenesis and organ targeting of exosomes.

Authors:  Jacky G Goetz; Vincent Hyenne; Shima Ghoroghi; Benjamin Mary; Annabel Larnicol; Nandini Asokan; Annick Klein; Naël Osmani; Ignacio Busnelli; François Delalande; Nicodème Paul; Sébastien Halary; Frédéric Gros; Laetitia Fouillen; Anne-Marie Haeberle; Cathy Royer; Coralie Spiegelhalter; Gwennan André-Grégoire; Vincent Mittelheisser; Alexandre Detappe; Kendelle Murphy; Paul Timpson; Raphaël Carapito; Marcel Blot-Chabaud; Julie Gavard; Christine Carapito; Nicolas Vitale; Olivier Lefebvre
Journal:  Elife       Date:  2021-01-06       Impact factor: 8.140

8.  Scar/WAVE3 contributes to motility and plasticity of lamellipodial dynamics but not invasion in three dimensions.

Authors:  Heather J Spence; Paul Timpson; Hao Ran Tang; Robert H Insall; Laura M Machesky
Journal:  Biochem J       Date:  2012-11-15       Impact factor: 3.857

9.  Inhibition of autophagy impairs tumor cell invasion in an organotypic model.

Authors:  Robin L Macintosh; Paul Timpson; Jacqueline Thorburn; Kurt I Anderson; Andrew Thorburn; Kevin M Ryan
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

10.  CYRI-A limits invasive migration through macropinosome formation and integrin uptake regulation.

Authors:  Anh Hoang Le; Tamas Yelland; Nikki R Paul; Loic Fort; Savvas Nikolaou; Shehab Ismail; Laura M Machesky
Journal:  J Cell Biol       Date:  2021-06-24       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.